Apatinib Has Anti-tumor Effects and Induces Autophagy in Colon Cancer Cells

Overview

Journal Iran J Basic Med Sci

Publisher Mashhad University of Medical Sciences

Specialty General Medicine

Date 2017 Nov 1

PMID 29085592

Citations 29

Authors

Wu Lu

He Ke

Ding Qianshan

Wang Zhen

Xiang Guoan

Yu Honggang

Affiliations

Soon will be listed here.

Abstract

Objectives: Apatinib recently has been used to treat patients with gastric cancer, but the function of apatinib in colon cancer remains unclear. This study was conducted to investigate the impacts of apatinib on the biological function and its potential mechanism of colon cancer cells .

Materials And Methods: The effect of apatinib in colon cancer cells were detected by assessing cell viability, migration and invasion capabilities. Apoptosis cells and the cell cycle distribution of colon cancer cells were analyzed by flow cytometry. The potential mechanism was investigated via autophagy related proteins and pathways .

Results: The proliferation, migration and invasion of colon cancer cells were inhibited when they were treated with different concentration of apatinib (20, 40 μM). When HCT116 and SW480 cells were treated with apatinib at the concentration of 20 μM, the apoptosis percentage were 3.7% and 5.8% respectively. As the drug concentration increased to 40μΜ, the the apoptosis percentage increased to 11.9% and 13.5%. Meanwhile, cell cycle was also altered. Furthermore, apatinib inhibited the expression of AKT-mTOR signaling pathway and increased the expression of LC3-II.

Conclusion: Apatinib can significantly inhibit the malignant phenotype of colon cancer cells, and it was involved in regulation of autophagy.

Citing Articles

Carnosic Acid against Lung Cancer: Induction of Autophagy and Activation of Sestrin-2/LKB1/AMPK Signalling.

ONeill E, Sze N, MacPherson R, Tsiani E Int J Mol Sci. 2024; 25(4).

PMID: 38396629 PMC: 10888478. DOI: 10.3390/ijms25041950.

Efficacy and safety of apatinib in patients with untreated or chemotherapy-refractory soft tissue sarcoma: a multicenter, phase 2 trial.

Yu W, Zhang H, Chen J, Zhang X, Chen Y, Qu G Ann Transl Med. 2022; 10(18):981.

PMID: 36267741 PMC: 9577792. DOI: 10.21037/atm-22-4229.

The role of autophagy in colorectal cancer: Impact on pathogenesis and implications in therapy.

Mahgoub E, Taneera J, Sulaiman N, Saber-Ayad M Front Med (Lausanne). 2022; 9:959348.

PMID: 36160153 PMC: 9490268. DOI: 10.3389/fmed.2022.959348.

Low- dose Apatinib promotes vascular normalization and hypoxia reduction and sensitizes radiotherapy in lung cancer.

Jiang S, Zhou Y, Zou L, Chu L, Chu X, Ni J Cancer Med. 2022; 12(4):4434-4445.

PMID: 36065943 PMC: 9972072. DOI: 10.1002/cam4.5113.

Apatinib: A Novel Antiangiogenic Drug in Monotherapy or Combination Immunotherapy for Digestive System Malignancies.

Li H, Huang H, Zhang T, Feng H, Wang S, Zhang Y Front Immunol. 2022; 13:937307.

PMID: 35844616 PMC: 9276937. DOI: 10.3389/fimmu.2022.937307.

References

Yang J, Carra S, Zhu W, Kampinga H . The regulation of the autophagic network and its implications for human disease. Int J Biol Sci. 2013; 9(10):1121-33. PMC: 3858585. DOI: 10.7150/ijbs.6666. View

Chatterjee S, Heukamp L, Siobal M, Schottle J, Wieczorek C, Peifer M . Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer. J Clin Invest. 2013; 123(4):1732-40. PMC: 3613914. DOI: 10.1172/JCI65385. View

Chan M, Sjoquist K, Zalcberg J . Clinical utility of ramucirumab in advanced gastric cancer. Biologics. 2015; 9:93-105. PMC: 4589126. DOI: 10.2147/BTT.S62777. View

Hu T, Li Z, Gao C, Cho C . Mechanisms of drug resistance in colon cancer and its therapeutic strategies. World J Gastroenterol. 2016; 22(30):6876-89. PMC: 4974586. DOI: 10.3748/wjg.v22.i30.6876. View

Levine B, Kroemer G . Autophagy in the pathogenesis of disease. Cell. 2008; 132(1):27-42. PMC: 2696814. DOI: 10.1016/j.cell.2007.12.018. View

Kim J, Kundu M, Viollet B, Guan K . AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol. 2011; 13(2):132-41. PMC: 3987946. DOI: 10.1038/ncb2152. View

Fornaro L, Vasile E, Falcone A . Apatinib in Advanced Gastric Cancer: A Doubtful Step Forward. J Clin Oncol. 2016; 34(31):3822-3823. PMC: 5477932. DOI: 10.1200/JCO.2016.68.6931. View

Mizushima N, Levine B, Cuervo A, Klionsky D . Autophagy fights disease through cellular self-digestion. Nature. 2008; 451(7182):1069-75. PMC: 2670399. DOI: 10.1038/nature06639. View

Scott A, Messersmith W, Jimeno A . Apatinib: a promising oral antiangiogenic agent in the treatment of multiple solid tumors. Drugs Today (Barc). 2015; 51(4):223-9. DOI: 10.1358/dot.2015.51.4.2320599. View

10.

Ivy S, Wick J, Kaufman B . An overview of small-molecule inhibitors of VEGFR signaling. Nat Rev Clin Oncol. 2009; 6(10):569-79. DOI: 10.1038/nrclinonc.2009.130. View

11.

Jayson G, Kerbel R, Ellis L, Harris A . Antiangiogenic therapy in oncology: current status and future directions. Lancet. 2016; 388(10043):518-29. DOI: 10.1016/S0140-6736(15)01088-0. View

12.

Parkin D . Global cancer statistics in the year 2000. Lancet Oncol. 2002; 2(9):533-43. DOI: 10.1016/S1470-2045(01)00486-7. View

13.

Ding J, Chen X, Gao Z, Dai X, Li L, Xie C . Metabolism and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor apatinib in humans. Drug Metab Dispos. 2013; 41(6):1195-210. DOI: 10.1124/dmd.112.050310. View

14.

Fontanella C, Ongaro E, Bolzonello S, Guardascione M, Fasola G, Aprile G . Clinical advances in the development of novel VEGFR2 inhibitors. Ann Transl Med. 2015; 2(12):123. PMC: 4260048. DOI: 10.3978/j.issn.2305-5839.2014.08.14. View

15.

Roviello G, Ravelli A, Fiaschi A, Cappelletti M, Gobbi A, Senti C . Apatinib for the treatment of gastric cancer. Expert Rev Gastroenterol Hepatol. 2016; 10(8):887-92. DOI: 10.1080/17474124.2016.1209407. View

16.

Lee J, Chu E . Sequencing of antiangiogenic agents in the treatment of metastatic colorectal cancer. Clin Colorectal Cancer. 2014; 13(3):135-44. DOI: 10.1016/j.clcc.2014.02.001. View

17.

Ahlberg J, Glaumann H . Uptake--microautophagy--and degradation of exogenous proteins by isolated rat liver lysosomes. Effects of pH, ATP, and inhibitors of proteolysis. Exp Mol Pathol. 1985; 42(1):78-88. DOI: 10.1016/0014-4800(85)90020-6. View

18.

Aoyama T, Yoshikawa T . Targeted therapy: Apatinib - new third-line option for refractory gastric or GEJ cancer. Nat Rev Clin Oncol. 2016; 13(5):268-70. DOI: 10.1038/nrclinonc.2016.53. View

19.

Thomas H, Coley H . Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control. 2003; 10(2):159-65. DOI: 10.1177/107327480301000207. View

20.

Roviello G, Ravelli A, Polom K, Petrioli R, Marano L, Marrelli D . Apatinib: A novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer. Cancer Lett. 2016; 372(2):187-91. DOI: 10.1016/j.canlet.2016.01.014. View